

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
13 June 2019 (13.06.2019)



(10) International Publication Number
WO 2019/112854 A1

(51) International Patent Classification:

A61K 38/20 (2006.01) A61P 37/02 (2006.01)
A61K 47/68 (2017.01) A61P 37/04 (2006.01)
A61P 29/00 (2006.01) A61P 37/06 (2006.01)

(21) International Application Number:

PCT/US2018/062808

(22) International Filing Date:

28 November 2018 (28.11.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/595,357	06 December 2017 (06.12.2017)	US
62/675,972	24 May 2018 (24.05.2018)	US
16/109,875	23 August 2018 (23.08.2018)	US
16/109,897	23 August 2018 (23.08.2018)	US
62/721,644	23 August 2018 (23.08.2018)	US

(71) Applicant: **PANDION THERAPEUTICS, INC.**
[US/US]; 700 Main Street, North, Cambridge, Massachu-
setts 02139 (US).

(72) Inventors: **HIGGINSON-SCOTT, Nathan**; 700 Main
Street, North, Cambridge, Massachusetts 02139 (US).
VINEY, Joanne L.; 700 Main Street, North, Cambridge,
Massachusetts 02139 (US). **VISWESWARAIAH, Jyothsna**;
700 Main Street, North, Cambridge, Massachusetts
02139 (US). **SAMPSON, Erik Robert**; 700 Main Street,
North, Cambridge, Massachusetts 02139 (US). **OTIPOBY,**
Kevin Lewis; 700 Main Street, North, Cambridge, Massa-
chusetts 02139 (US).

(74) Agent: **SCOLNICK, Daniel M.**; Pepper Hamilton LLP,
400 Berwyn Park, 899 Cassatt Road, Berwyn, Pennsylvania
19312 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,


SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: IL-2 MUTEINS AND USES THEREOF



(57) Abstract: Described herein are therapeutics that can modulate (e.g. increase) T-reg cell proliferation, survival, activation and/or function. In some embodiments, the modulation is selective or specific for the T-reg cells. The present application provides for IL-2 muteins, compositions comprising the same, and methods of using the same. In another aspect, the present embodiments provide compositions, e.g., pharmaceutically acceptable compositions, which include a therapeutic compound (IL-2 mutein) described herein, formulated together with a pharmaceutically acceptable carrier. Also within the scope of the invention is a kit comprising a therapeutic compound described herein.